Full Year Revenue: $359 billion, a 16% increase from the prior year. Adjusted Earnings Per Diluted Share (EPS): $33.05, a 20% year-over-year growth. Cash Returned to Shareholders: $3.5 billion. Fourth Quarter Revenue: $90.8 billion, a 19% increase. Fourth Quarter EPS: $10.12. Fourth Quarter Gross Profit: $3.4 billion, a 2% increase. Fourth Quarter Operating Expenses: $1.9 billion, a 10% decrease. Fourth Quarter Operating Profit: $1.6 billion, a 24% increase. US Pharmaceutical Segment Revenue: $83.2 billion, a 21% increase. Prescription Technology Solutions Revenue: $1.3 billion, a 13% increase. Medical Surgical Solutions Revenue: $2.9 billion, a 1% increase. International Segment Revenue: $3.5 billion, a 2% decrease. Free Cash Flow: $7.5 billion in the fourth quarter. Fiscal 2026 Revenue Growth Outlook: 11% to 15%. Fiscal 2026 EPS Outlook: $36.75 to $37.55. Warning! GuruFocus has detected 6 Warning Sign with MCK. Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points McKesson Corp (NYSE:MCK) reported a 16% increase in full-year consolidated revenues, reaching a record $359 billion. Adjusted earnings per diluted share grew by 20%, surpassing long-term growth targets. The company returned $3.5 billion of cash to shareholders, demonstrating strong cash flow management. Strategic acquisitions in oncology and other specialties, such as PRISM Vision and Core Ventures, are expected to accelerate growth. The Prescription Technology Solutions segment experienced double-digit growth in adjusted operating profit, driven by strong demand for access and affordability solutions. Negative Points The divestiture of Canadian businesses, including Rexall and Well.ca, resulted in lower contributions from the International segment. Operating expenses decreased by 10% due to divestitures and cost optimization, which may indicate potential downsizing or restructuring. The Medical Surgical segment experienced softer volumes in the primary care market, impacting growth. The company faces a dynamic market environment with uncertainties in policies and macroeconomic conditions. Free cash flow guidance for fiscal 2026 is lower than the previous year, reflecting potential cash outflows for acquisitions. Q & A Highlights Q: Can you help us understand the potential impact of Medicare Part B MFN on McKesson's core distribution and specialty clinics business? A: Brian Tyler, CEO: Currently, nothing has been officially announced, and any changes would likely face legal challenges. Community-based care is crucial for accessible, high-quality, and low-cost care, especially in oncology. We believe community-based care will continue to be fairly compensated. On the distribution side, McKesson expects to be paid fair value for its services. Story Continues Q: How are tariffs expected to impact McKesson's business, particularly in fiscal '26? A: Brian Tyler, CEO: We are closely monitoring the tariff landscape and have incorporated current policies into our guidance. Our sourcing strategy is diversified, and we have flexibility in pricing to mitigate tariff impacts. Britt Vitalone, CFO, added that the impact is not expected to be material for fiscal '26. Q: With the separation of MedSurg, is there increased urgency to invest in biopharma services? A: Brian Tyler, CEO: The urgency to invest prudently against our strategy remains unchanged. We focus on financial discipline and strategic alignment. Opportunities are pursued when they align with our strategy and financial goals. Q: What factors contribute to the increased long-term growth guidance for the US Pharmaceutical segment? A: Brian Tyler, CEO: The increase reflects stable prescription utilization, strategic customer onboarding, and a differentiated growth platform in oncology. Britt Vitalone, CFO, noted that the segment's growth is driven by strategic acquisitions and operational efficiencies. Q: Can you elaborate on the trends in SG&A and gross profit for the quarter? A: Britt Vitalone, CFO: The decline in SG&A is primarily due to divestitures in the Canadian business. The gross profit trend reflects a mix of divestitures and operational leverage, contributing to strong adjusted operating profit. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
McKesson Corp (MCK) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...